CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
Authors
Keywords
-
Journal
Hematology Transfusion and Cell Therapy
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-09-20
DOI
10.1016/j.htct.2022.08.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients
- (2022) Minghao Li et al. Scientific Reports
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
- (2022) Noopur S Raje et al. Lancet Haematology
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T-cell therapy in multiple myeloma: more room for improvement
- (2021) Phaik Ju Teoh et al. Blood Cancer Journal
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
- (2021) Larry D. Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
- (2021) Angelo Maiolino et al. Hematology Transfusion and Cell Therapy
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VI: Accreditation process
- (2021) Gil Cunha De Santis et al. Hematology Transfusion and Cell Therapy
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
- (2021) P.J. Hayden et al. ANNALS OF ONCOLOGY
- CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy
- (2019) Joshua A. Hill et al. BLOOD REVIEWS
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
- (2019) Thierry Facon et al. LEUKEMIA
- Treatment Options for Triple-class Refractory Multiple Myeloma
- (2019) Joseph Mikhael Clinical Lymphoma Myeloma & Leukemia
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- The EBMT risk score
- (2011) A Gratwohl BONE MARROW TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started